Obstetrical and Perinatal Outcomes Are Not Associated with Advanced Paternal Age in IVF or ICSI Pregnancies with Autologous Oocytes

Biology (Basel). 2023 Sep 20;12(9):1256. doi: 10.3390/biology12091256.

Abstract

Background: In recent years, there has been an evident delay in childbearing and concerns have been raised about whether this increase in age affects reproductive outcomes. This study aimed to evaluate the effect of paternal age on obstetrical and perinatal outcomes in couples undergoing in vitro fertilization or intracytoplasmic sperm injection using autologous sperm and oocytes.

Methods: This retrospective study evaluated obstetrical and perinatal outcomes from 14,125 couples that were arbitrarily divided into three groups according to paternal age at conception: ≤30 (n = 1164), 31-40 (n = 11,668) and >40 (n = 1293). Statistics consisted of a descriptive analysis followed by univariate and multivariate models, using the youngest age group as a reference.

Results: The study showed significantly longer pregnancies for the fathers aged 31-40 compared to ≤30 years. However, there were no significant differences for the type of delivery, gestational diabetes, anaemia, hypertension, delivery threat, premature rupture of membranes, preterm birth, very preterm birth, and the neonate's sex, weight, low birth weight, very low birth weight, length, cranial perimeter, Apgar score and neonatal intensive care unit admission.

Conclusion: Despite our promising results for older fathers, as paternal age was not associated with clinically relevant obstetrical and perinatal outcomes, future well-designed studies are necessary as it has been associated with other important disorders.

Keywords: ART; ICSI; IVF; autologous oocytes; autologous sperm; obstetrical outcomes; offspring’s health; paternal age; perinatal outcomes; pregnancy.

Grants and funding

This research received no external funding. A.N.-G. is supported by the Ministerio de Ciencia, Innovación y Universidades (Spain) (FPU19/06126). M.G.J. is supported by the Instituto de Salud Carlos III (FI19/00051 2019/0172). R.M.P.-R. is supported by the Generalitat Valenciana (Spain) (CIACIF/2021/016).